Therapeutic Solutions International Inc (TSOI)

[cantbelieveit]

$TSOI New Facebook Post on Pterostilbene inhibiting tumor growth when used in combination with the FDA-approved drug. Don't know if the graph will show in this text box.

Therapeutic Solutions International, Inc.
February 6 at 9:44am ·
Synergistic Inhibition of B16 Melanoma
The following example demonstrates that pteros­tilbene in combination with IL-2 synergistically inhibits B16 melanoma in mice.
Female C57BL/6 mice aged 8-12 weeks were purchased from The Jackson Laboratory. A murine mela­noma cell line established from a C57BL/6 mouse and designated B16F10 was obtained from the American Type Culture Collection (ATCC) and was maintained in RPMI 1640 medium (Sigma-Aldrich) with 10% FBS, 1-glutamine, penicillin, and streptomycin at 37° C. in 5% CO2 The cell line was cultured at 37° C. in a 5% incubator.
For induction of tumor growth, 5xl05 B16 cells were injected subcutaneously into the hind limb flank. Tumor growth was assessed every 3 days by two measure­ments of perpendicular diameters by a caliper, and animals were sacrificed when tumors reached a size of 1 cm in any direction. Tumor volume was calculated by the following formula: (the shortest diameter2xthe longest diameter)/2. Mice treated represent 15 mice per group.
Animals were treated every second day with: Group A) Saline (diamonds-<)); B) pterostilbene; 25 µg/kg (squares-D), C) IL-2; 500 IV/mouse (triangles-fl); and D) a combination of IL-2 and pterostilbene at the indicated concentrations (X). As shown in FIG. 1, tumor growth is inhibited by the administration of the combination of 25 µg/kg pterostilbene and 500 IV/mouse IL-2.
Image may contain: sky
LikeShow more reactionsCommentShare
https://www.facebook.com/tsoihome/?rc=p